On the other hand, other traditional drugs, such as methotrexate, have neutral effect on the cardiovascular risk in psoriasis, whereas biologic agents, such as IL-17A inhibitors, result in improvement of arterial and myocardial function [1]. The gene discussed is IL17A; the disease is psoriasis.